KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cost of Revenue: 2016-2024

Historic Cost of Revenue for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $1.8 billion.

  • Amneal Pharmaceuticals' Cost of Revenue rose 17.93% to $510.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 7.09%. This contributed to the annual value of $1.8 billion for FY2024, which is 12.74% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Cost of Revenue is $1.8 billion, which was up 12.74% from $1.6 billion recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Cost of Revenue high stood at $1.8 billion for FY2024, and its period low was $1.3 billion during FY2021.
  • Over the past 3 years, Amneal Pharmaceuticals' median Cost of Revenue value was $1.6 billion (recorded in 2023), while the average stood at $1.6 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Cost of Revenue increased by 15.89% in 2020 and then fell by 0.37% in 2021.
  • Over the past 5 years, Amneal Pharmaceuticals' Cost of Revenue (Yearly) stood at $1.3 billion in 2020, then declined by 0.37% to $1.3 billion in 2021, then rose by 7.77% to $1.4 billion in 2022, then rose by 10.19% to $1.6 billion in 2023, then grew by 12.74% to $1.8 billion in 2024.